文献速递免疫规划传染病防控与疫情报告

Ad5-nCoV疫苗两剂与一剂相对效力、安全性及免疫原性分析

Relative efficacy, safety, and immunogenicity analysis of two doses versus one dose of recombinant coronavirus vaccine (adenovirus type 5 vector) in adults 18 years and older: an international, multicentre, randomized, double blinded phase 3 trial.
PubMed 文献 · Vaccine · 2026-03-19

基于国际多中心随机双盲3期试验,既往接种一剂Ad5-nCoV者补种一剂后,两剂组与一剂组相比,防有症状COVID-19的相对疫苗效力(rVE)为34.12%,差异无统计学意义;但两剂组对重症的相对效力为79.5%,且加强后抗体滴度更高、严重不良事件更少。结论认为两剂与一剂均有效安全,第二剂可提升对重症的保护和免疫原性。

要点

  • 两剂与一剂相比,防有症状COVID-19的rVE 34.12%,差异无统计学意义。
  • 两剂组对重症的相对效力为79.5%(95%CI 28.1%–94.2%)。
  • 两剂组接种后28天Spike-RBD IgG和中和抗体分别高1.7倍和4.4倍。

核心结论

  • 两剂和一剂Ad5-nCoV疫苗均有效、安全且具有免疫原性。
  • 第二剂可提升对重症疾病的保护和免疫原性。

研究设计与样本

  • 国际多中心、随机、双盲、安慰剂对照3期试验的延伸随访研究。
  • 受试者为18岁及以上健康成人,来自阿根廷、智利、墨西哥、巴基斯坦和俄罗斯的研究中心。
  • 既往研究受试者于2021年6月8日起接种一剂Ad5-nCoV(中位时间为首针后6个月),使原疫苗组接受两剂、原安慰剂组接受一剂。
  • 随访至接种后24周,监测COVID-19疾病、安全性和抗体反应。

主要发现

  • 主要效力分析触发时共83例终点病例,两剂与一剂相比rVE为34.12%(95%CI -1.31至57.15,n=8266),差异无统计学意义。
  • 研究结束分析(截止2022年1月28日)显示,接种后28天起rVE为6.3%(95%CI -8.7至19.2)。
  • 重症疾病相对效力为79.5%(95%CI 28.1%至94.2%,接种后28天起)。
  • 严重不良事件(≥4级)一剂组12例(0.12%)多于两剂组4例(0.04%),p=0.043;需医疗关注的不良事件分别为9例(0.090%)和1例(0.009%),p=0.009。
  • 接种后28天,两剂组Spike-RBD IgG和中和抗体滴度分别较一剂组高1.7倍和4.4倍,抗体反应至24周时减弱。

关键数值与推荐

  • 主要效力分析评估接种后至少28天预防PCR确诊COVID-19疾病的rVE≥10%(两剂 vs 一剂)。
  • 研究结束分析中重症疾病rVE为79.5%(95%CI 28.1%至94.2%)。
  • 严重不良事件(≥4级)发生率一剂组0.12% vs 两剂组0.04%(p=0.043)。
  • 需医疗关注的不良事件发生率一剂组0.090% vs 两剂组0.009%(p=0.009)。
  • 接种后28天Spike-RBD IgG和中和抗体滴度两剂组较一剂组分别高1.7倍和4.4倍。

临床怎么用

  • 在已完成一剂Ad5-nCoV接种的成人中,可考虑补种第二剂以增强对重症COVID-19的保护。
  • 补种第二剂后需关注抗体反应随时间的减弱,适时评估加强免疫策略。
  • 接种后应监测严重不良事件和需医疗关注的不良事件,两剂方案未见更高风险。

局限性

  • 主要效力分析时两剂与一剂的rVE差异无统计学意义,效力比较需结合置信区间解读。
  • 抗体反应在接种后24周内减弱,长期保护数据未报告。
  • 研究结束分析中总体rVE置信区间跨越零,总体症状性感染保护差异不确定。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: An international, double-blind, placebo-controlled phase 3 study in healthy adults previously showed one dose of the Ad5-nCoV vaccine was efficacious (57.5%) against symptomatic COVID-19 infection, especially severe disease, was safe, and immunogenic (ClinicalTrials.gov, NCT04526990). The current study extends that report to assess relative vaccine efficacy (rVE), safety, and immunogenicity of two doses versus one dose of Ad5-nCoV vaccine. METHODS: Participants from the prior (part-one) study who continued to the follow-up study (part-two) herein were provided an Ad5-nCoV dose at study sites in Argentina, Chile, Mexico, Pakistan, and Russia, starting June 8th 2021 (median = 6 months post-first-injection). This injection led to two doses and one dose received by the prior vaccine and placebo recipients, respectively. Participants were monitored for COVID-19 disease, safety, and antibody responses up to 24 weeks post-vaccination. RESULTS: The endpoint of 83 cases occurred August 9, 2021, triggering primary efficacy analysis which evaluated rVE ≥10% (two versus one dose) of Ad5-nCoV in preventing PCR-confirmed COVID-19 disease at least 28 days post-vaccination. rVE (34.12%) was non-significant (95% CI -1.31 to 57.15, n = 8266), indicating similar efficacy of dose groups. End-of-study analysis (cutoff January 28, 2022) showed rVE was 6.3% (95% CI -8.7 to 19.2, starting 28 days), and for severe disease was 79.5% (95% CI 28.1% to 94.2%, starting 28 days). Serious adverse events (SAEs, ≥grade 4) were more frequent after one dose (12 [0.12%]) than two doses (4 [0.04%], p = 0.043), as were medically attended adverse events (9 [0.090%] and 1 [0.009%], p = 0.009). One SAE (myocarditis) was related to the study-product. Spike-RBD IgG and neutralization antibody titers were elevated for two-dose versus one-dose recipients (1.7- and 4.4-fold) at 28-days post-vaccination. Antibody responses waned by 24 weeks. CONCLUSION: Two doses and one dose of Ad5-nCoV vaccine are efficacious, safe and immunogenic. A second dose improves protection against severe disease and immunogenicity. TRIAL REGISTRATION: The trial is registered at ClinicalTrials.gov (NCT04526990).

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Rooyakkers A, Ye L, Cahn PE, et al. Relative efficacy, safety, and immunogenicity analysis of two doses versus one dose of recombinant coronavirus vaccine (adenovirus type 5 vector) in adults 18 years and older: an international, multicentre, randomized, double blinded phase 3 trial. Vaccine. 2026. PMID: 41863180. doi:10.1016/j.vaccine.2026.128424

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。